

Index

a

- acetaldehyde production, in
Streptococcus thermophilus
 574–575
- acetate 472
 acetate-to-acetyl-CoA process 750
 production 749
- acetoin 196, 432, 472, 492, 495, 558,
 575–578
- acetolactate synthase (ALS) 196, 354,
 697, 706
- acetone–butanol–ethanol (ABE)
 metabolic route 611, 613
 butanol production 698
- acetyl-CoA 14–15, 738
 cytoplasmic acetyl-CoA 713
 cytosolic acetyl-CoA 746, 750, 753,
 754
- AcidifyME model 48
- actinomycetes
 CRISPR-based genome editing
 techniques 663–665
 generalized systems metabolic
 engineering workflow for
 672
 genome editing of 663
- actinomycetes synthetic biology
 biological parts of 665, 667–669
 biosensors 669–670
 full pathway refactoring 671
 riboswitches 670–671
- activity-independent screening of target
 molecule synthesis 492–493
- acyl carrier proteins (ACPs) 354–356,
 370, 377, 699–702
- adaptive laboratory evolution (ALE)
 50, 285, 343, 384, 493, 499,
 534, 555, 566, 567–570, 694
- adenosine triphosphate (ATP) 31, 102,
 140, 147–148, 180, 188, 191,
 194, 196, 213, 224, 284, 354,
 355, 362, 424, 427, 434, 477,
 487, 495–496, 522, 524,
 528–529, 532, 555, 558, 585,
 631, 693, 701, 704–705, 714,
 740, 742, 744–746, 748–751,
 775–777, 808–809
- α -ketoglutarate (α KG) production 363,
 420, 427, 703, 736, 738,
 740–744, 750
- alanine 117, 374, 416, 574
- alanine (ALA_{2,3}) 117
- alarmones guanosine tetra- and
 penta-phosphate 471
- alcohol dehydrogenase (ADH) 283,
 343, 354, 356, 359–360, 363,
 432, 576–577, 583–585, 613,
 692–693, 695, 697–698,
 700–702, 704
- algae biomass 829
- algal biomass 415
- alkaloids 367, 368, 370, 713, 775, 812,
 817, 820, 824–825
 production, in *S. cerevisiae*
 710–712
- alkane biosynthetic pathway 702
- alleleome 33–34
- Allelic Coupled Exchange (ACE)
 couples 618, 703

- amino acids
 - aminovalerate 421–423
 - L-arginine 364
 - auxotrophic markers 745
 - cell factory 403
 - ectoine 425–426
 - L-glutamate 419–420
 - 4-HIL production 427
 - L-lysine 420–421
 - L-pipecolic acid 426
 - L-theanine 427
 - L-threonine 364
 - trans*-4-hydroxyproline 426–427
 - L-valine 365
- ω -amino acids
 - 4ABA 357
 - 5AVA 357–359
- 4-aminobutyric acid (4ABA) 357, 363
- 6-aminocaproic acid 357, 359, 363
- aminovalerate 359, 421, 422, 430–431
- 5-aminovaleric acid (5AVA) 357, 359, 361, 362, 423
- anaerobic reporter 631
- anaplerosis 74, 101
- anaplerotic glyoxylate pathway 472
- anhydrotetracycline (aTc)-inducible systems 627
- anoxic *P. putida* chassis 531
- anthocyanin 588, 709, 818–820, 834–835
- antimicrobial activity (AA), of
 - bacteriocins 557, 582
- anti-CRISPR proteins 620
- antibiotic resistance genes 302, 479, 615, 868–869, 878
- antibiotics 302, 313, 317, 365–366, 406, 496, 561, 581, 583, 653, 665–666, 673–676, 769, 780–781, 788–789, 865
- Antirrhinum majus* 819
- antiSMASH 658–660
- approximative rate expression
 - 159–160
- aquatic cyanobacteria 806
- Arabidopsis thaliana* 180, 356, 588, 632, 710, 806, 815
- arabinose 408, 413–415, 420, 432, 523, 571–572, 495, 697
- arabinoxylans 412, 415, 816
- L-arginine 364, 403, 405, 419
- aromatic amino acids 824
 - bacterial production of 200–202
 - bisynthesis, in *S. cerevisiae* 708
 - synthesis 824
- aromatic compounds
 - mandelic acid 366
 - methyl anthranilate 366
 - S*-styrene oxide 366, 367
 - L-tyrosine 365, 366
- artemisinic acid production 369, 713, 715
- Aspart 720
- Aspartate transcarbamylase (ATCase) 188
- Aspergillus niger* 765, 766, 776, 785, 789
 - enzyme set for plant polysaccharide degradation 773
 - genom-scale metabolic models 770
 - glucoamylase 777
 - hyperbranching strain 786
 - metabolic and regulatory functions 771
 - X-ray microcomputed tomography (μ CT) 788
- Aspergillus oryzae* 766, 778
 - enzyme set for plant polysaccharide degradation 773
- Aspergillus terreus* 430, 767, 779–780
- asRNA knockdown method 625
- atmospheric pressure chemical ionization (APCI) 269
- atom enumeration scheme 103–104
- atom transition network 91, 92, 94–95, 104
- atom transition network specification 103
- atom transitions 91–92, 97, 99, 103–104
- auto-scaling 275
- azadirachtin 817

b

- Bacillus amyloliquefaciens* strains 472, 493
- Bacillus subtilis* 469
- B. subtilis* ATCC6051a 482
- B. subtilis* BSK814 475
- B. subtilis* MGB469 475
- B. subtilis* MGB874 475
- CRISPR/Cas and related strains 481–486
- genome reduction projects 473–476
- Bacillus licheniformis* 470
- B. licheniformis* 2709 482
- isocitrate lyase (aceB) 472
- Bacillus thuringiensis cry3Bb* gene 829
- Bacillus* BioBrick Box 490
- Bacillus* origin of replication (*ori*) 481
- bacitracin 486, 494, 496–497
- 42.7 kb bacitracin synthase gene cluster *bacABC* 486
- backslipping process 566
- bacterial 3-dehydroshikimate dehydratase 816
- bacterial cellulose 379–380
- bacteriocins production, in LAB 581
- bacteriophage infections 565
- basic helix-loop-helix (bHLH) transcription factor 818–819
- batch cultures 109, 111, 112, 356, 530
- benzylisoquinoline alkaloids (BIAs) 370, 710–712
- bioactive natural products 653, 804
- biosynthetic pathways 655, 667, 668
- tools and strategies for discovery 653–655
- bioaugmentation 861–862
- biochemical databases 238, 240, 244, 251
- biochemical network 166, 240, 242–243, 249
- biochemical search space 238, 240
- Biochemical Systems Theory (BST) 173, 175
- biocondensates 803, 833–835
- bioenergetics 213–214
- bioethanol production
- first-generation 691–694
- second generation 694–697
- bioluminescent reporters 631
- biomass effluxes 102–103
- bioproducer strains 238
- bioproduction 243, 253–254, 285, 408, 415, 519, 530–531, 535, 780, 810–811, 817, 829–830, 873
- bioremediation 875
- challenges 859
- chemical emissions and parameters 862, 867
- definition 859
- transition from 2.0 to 3.0 862
- bioremediation 3.0 862–865, 867–869
- bioremediation 4.0 879–880
- bioremediation agent 521, 861, 862, 865, 870, 872, 878–879
- P. putida* 873
- biosensors 13, 16, 383, 493, 525, 669, 670, 865
- biostimulation 861–862
- biosustainable industrial production platforms 806–808
- biosynthetic gene clusters (BGCs) 655, 657
- cloning and heterologous expression 660–663
- genome mining 657–660
- promoter engineering 667
- reporter-guided mutant selection (RGMS) 670
- biosynthetic pathways
- of natural products 655, 657
- search for 251
- block elasticities 186
- blood proteins 721
- B. methanolicus* MGA3 482, 489
- bondomers 121
- bottromycin biosynthetic pathway 667
- branched chain amino acids (BCAA) 359, 365, 496, 552
- branched-chain alcohols 354
- BsubCyc 470

- butanediol (BDO)-isomers 577
 1,4-butanediol 57, 249, 363
 2,3-butanediol 472, 494, 706
 butanol 343, 697
 production of 343, 588, 611–613,
 698–699
 butyrolactam 357, 363
- C**
- cadaverine 359, 361–362, 423
 camalexin 833
 cannabidiolic acid synthase 837
Cannabis sativa 834, 837
 cannibalism 374, 471, 478
 capillary electrophoresis (CE) 267
 capitata-stalked trichome 834, 837
 caprolactam 363, 533
 Carbohydrate-Active enzyme database
 (CAZy) 773
 carbon atom transitions 91–92
 carbon catabolite repressor 496
 β -carotene production 758, 759, 820
 carotenoids 433, 524, 713, 718, 758,
 817, 820, 826, 828–830
 Cas-enzymes 308, 310, 312, 316, 320
 Cas12a (Cpf1) enzyme 312, 663
 Cas9 nickase (Cas9n) systems 482, 620
 Cas9-Assisted Targeting of
 CHromosome segments
 (CATCH) 662
 Cas9-mediated mutagenesis 564
Caulobacter crescentus 379, 413, 473
 CAZyme gene expression, molecular
 mechanism of 773
 cell type specific metabolic engineering
 815
 cell-free *in vitro* transcription systems
 865
 cell-free agents 860
 cellular compartments 103, 282, 718,
 834
 cellular constraints 137–139
 cellulase Egl-237 477
 CeluStar CL 783
 central carbon intermediates 112
 13CFLUX2 117
 $^{13}\text{C}_1$ glucose 106
 chalcone isomerase (CHI) 369, 417,
 418, 708, 709
 chalcone synthase (CHS) 369, 417,
 418, 708, 709
 chassis development 861
 chassis for bioremediation 873
 chassis metabolic model 246
 chemical ionization (CI) 269
 Chinese Hamster Ovary (CHO) 166,
 188, 317–320
 ChIPseq 61
Chlamydomonas reinhardtii 806, 830
 chloramphenicol acetyltransferase
 (CAT) reporter 630
 chlorophyll 822, 825–826, 828, 829
 chloroplast stroma-localized ferredoxin
 (AtFedA) 825
 chloroplast thylakoid 809, 826
 chloroplasts 805, 806, 810, 821–830,
 834–835, 837
 chromosome-less bacteria (SimCells)
 860
 cinnamic acid 367, 707, 708, 819
 circular gRNA-containing plasmids
 311
cis,cis-muconate 428, 429
cis-cis-muconic acid 417
 in *P. putida* 533, 534
 citrate production 739, 745–746
Y. lipolytica 738
 citrate synthase CitZ 496
 citric acid production 765, 780, 788
 in *A. niger* 776
 ^{13}C -labeled substrate 77
 Class II and Class I diterpenoid
 synthases 822
 cloning, of BGCs 661
Clostridium
 5'-UTRs & Riboswitches 634
 genetic parts 626–627
 promoters 627–630
 reporters 630
 enzymatic-based reporters
 630–631
 bioluminescent reporters 631
 fluorescent reporters 631–632

- FbFP-based fluorescent reporters 632–633
- FAST, HaloTag, and SNAP-tag fluorescent reporters 633
- genome editing 614–615
 - ClosTron system 615
 - counter-selection markers 617–619
 - CRISPR systems 619–626
 - transposon-based random mutagenesis 615–617
- terminators 633–634
- ClosTron systems 615
- cloud microbiology 879
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 304, 308, 309, 619, 625
 - associated (Cas) genes 308
 - based metabolic engineering, in *T. thermophilus* 783
 - mediated gene manipulation systems, for filamentous actinomycetes 664
 - technology, for *C. glutamicum* 407
- ¹³C metabolic flux analysis 76, 98, 162, 404, 406, 413, 415, 420, 739–740, 748
- 2-C-methyl-D-erythritol-4-phosphate pathway 496
- codBA* system 479
- CO₂ fixation 15, 535, 783, 806, 811, 830
- coarse grained thermodynamic information 31
- coarse-grained integration of proteome constraints 139–144
- cobalamin (vitamin B12) production 578, 579
- coclaurine *N*-methyltransferase (CNMT) 370
- Coleus forskohlii* 823, 834
- combinatorial biosynthesis 662, 667, 670
- combinatorial metabolic engineering 9, 12–14
 - combinatorial supertransformation of transplastomic recipient lines (COSTREL) 828–829
- computational pathway design 238, 239, 252, 253
- computer-aided simulation 172
- concentration control coefficient 179–180, 185, 188
- confidence intervals (CoI) 89–90, 229
- conjugative transposons 615
- connectivity matrix 31
- conserved metabolites 186
- constrained optimization 26
- COntstraint-Based Reconstruction and Analysis (COBRA) method 26–28, 30, 41, 51, 62, 240
- continuous culture 77, 83, 110–113, 174
- COPI vesicles 719–720
- COPII cargo proteins 720
- core phenylpropanoid biosynthesis 819
- CoReCo metabolic model
 - reconstruction algorithm 770
- Corynebacterium glutamicum* 191, 194, 403, 437, 473
 - aquatic sugars 415–416
 - amino acids 419–427
 - biopolymers 434–436
 - CRISPR technology 407
 - genome editing approaches 406
 - hemicellulosic biomass 408, 409, 412
 - industrial product production 419
 - natural products and active ingredients 433
 - industrial raw materials 407–408
 - lignin aromatics, valorization of 416–419
 - lignocellulosic sugars 408–415
 - L-lysine production 404
 - marker-free genome editing 407
 - metabolome analysis 405
 - organic acids and alcohols 427
 - cis-cis* muconate 428–429
 - 3-hydroxypropionate 430–432

- Corynebacterium glutamicum* (contd.)
 glutarate production 429–430
 itaconate 430
 short-chain alcohols 432
 plasmid-based expression 406
 systems biology 404
 systems metabolic engineering 404
 Cosmid/fosmid library vectors 662
 coumarins 817
 biosynthesis 706, 708, 817
p-coumaroyl-CoA 707, 816
 counter-selection and markerless
 genome editing 478–481
 counter-selection markers 616,
 617–619
 coupling constraints 144–145,
 147–150
 Crabtree effect 141, 142, 150
¹⁴C radioisotope 80
 Cre/*loxP* system 315, 479, 561
 CRISPR-BEST system 665, 666
 CRISPR-Cas-technology 304, 313
 -based genome editing 314
 in *B. subtilis* and related strains
 481–486
 LAB genome editing 563–565
 CRISPR-Cas9
 and Cas12a-based genome editing
 methods 663
 based approach 873
 based genome editing 481, 489
 CRISPR-dCas9
 mediated base editing 488–489
 mediated cytosine deaminase base
 editing system 489
 mediated deaminase base editing
 489
 CRISPR interference (CRISPRi)
 487–490, 497, 564–565,
 625–626
 CRISPR interference and activation
 (CRISPRi/a) 487, 489
 CRISPR/*PmanPA*-Cas9 vectors 486
 CRISPR RNAs (crRNAs) 308, 624
 CRISPR/SpCas9-based genome editing
 system 490
 cross collisional section (CCS) 267
 cross-over theorem 179
 cucurbitacin synthesis 4
 cumomers 121
 cutin 813
 cyanobacteria 356, 805–806, 808, 811,
 822, 825–826, 829–831, 873
 cyanogenic glucosides 817–818, 820,
 824, 832–833
 cyanophycin 380–381
 cyborgization of bacterial strains 863
 cyclodepsipeptides (CDPs) 784–785
 cytochrome P450 (CYP) enzymes 369,
 701, 707–708, 710, 714, 812,
 816, 826
 cytochrome P450 oxidoreductase 2
 816
 cytoplasmic acetyl-CoA 713, 716
 cytosolic acetyl-CoA 705, 717, 736,
 746–747, 750, 756, 757
 availability 698, 753–754
- d**
 data analysis, in metabolomics
 multivariate statistics 278
 pathway analysis 278–279
 univariate statistics 277–278
 untargeted MS data processing
 273–277
 data dependent acquisition (DDA) 272
 data-independent acquisition (DIA)
 272
Daucus carota 818
DcMYB6 818
Del/Ros1 transgenic plant 819
 $\Delta 9$ stearoyl-CoA desaturase (D9) 746,
 747
de novo triacylglycerols biosynthesis
 745–746
 dead' Cas9 (dCas9) 309
 Debye–Hückel approximation 216,
 221–223
 deep allelome 34
 2-dehydro-3-deoxy-phosphogluconate
 aldolase reaction 91–92
 dehydrogenase 92
 alcohol 283, 343, 354, 356, 359–360,
 363, 432, 576–577, 583–585,

- 613, 692–693, 695, 697–698,
700–702, 704
- GAP 428, 432, 748–749
- lactate 196, 362, 377, 423–424,
434–435, 554, 571–573, 577,
587–588
- 3-dehydroshikimate 428–429, 816
- deoxyviolacein 433
- desorption electrospray ionization
(DESI) 269
- dhurrin synthesis 835
- diacetyl production 574
- diamines 360–361
- 1,3-diaminopropane 360
- cadaverine 361
- putrescine 361
- diaminopimelate 92, 359, 416, 421,
422, 431
- 1,3-diaminopropane 360–361
- dicarboxylic acids 361–362
- glutaric acid 361, 362
- succinic acid 362
- dihydrofolate reductase (DHFR)
317–318
- L-3,4-dihydroxyphenylalanine
(L-DOPA) 370
- dimethylallyl diphosphate (DMAPP)
355, 367, 369, 713–716,
757–758, 822
- diols
- 1,4-butanediol 363
- production 706
- 1,3-propanediol 362–363
- “direct” omics approach 100
- diterpenoid forskolin 834–835
- diterpenoids 821, 830
- DNA double-strand break (DSB)
489
- DNA double-strand breaks (DSB)
302–303, 305, 307–314,
317–318, 407, 489, 563–565,
619–620, 624, 626, 663–665
- DNA microarray analysis 722
- DNA microarrays 405
- docosanol 702
- L-DOPA decarboxylase (DODC) 370
- double crossover 615–619
- double-gene knockout (DKO)
predictions 34
- double-helix model 320
- double-stranded breaks (DSBs) 302
- Drosophila* DNA-binding Ubx
homeodomain 305
- dSpy*Cas9 625
- dual plasmid approaches 482
- dwarf-type mutants 814
- D-xylose 695, 697
- dynamic degradation of TAG' (ddTAG)
strategy 673
- dynamic mass balances 23–25, 28
- dynamic metabolons 831
- e**
- ecModels 140, 142, 144–145, 147,
150–151
- ectoine production 425–426
- EDEMP cycle 524–525
- Ehrlich degradation pathway 354
- eicosapentaenoic acid (EPA) 755–756,
760, 830
- electron impact (EI) ionization 269
- electrospray ionization (ESI) 268–269,
280–281
- Elementary Metabolite Units (EMU)
121
- Embden–Meyerhof–Parnas pathway
524
- Embryophyta 806
- emodepside 785
- enantiopure L-lactic acid production
572
- endogenous chloroplast-localized
NADP-malic enzyme 810
- endometabolomics 260
- endonucleases
- CRISPR 308–310
- TALEs 306–308
- ZFN 304–306
- endoplasmic reticulum (ER) 8, 701,
745–746, 750, 778, 818
- endoplasmic reticulum-associated
protein degradation (ERAD)
719
- endoxylanases 436

- energy-demanding sporulation process 471
 - energy-rich adenosine triphosphate (ATP) 808
 - Entner–Doudoroff pathway 92, 101, 282, 283, 524
 - environmental biocatalysts, development of 870
 - environmental Galenics 861, 877–*Environmental Galenic Science* 877
 - environmental microbiology 865
 - environmental microbiomes, fortification of 879
 - environmental pollution 859, 865, 867, 874
 - microbiological agents for bioremediation 860
 - enzymatic rate equations 25
 - enzyme abundance 155–156, 163
 - enzyme bottom–up approach 186
 - enzyme kinetics
 - factors affecting intracellular enzyme kinetics 155–156
 - Michaelis–Menten formula 153–154
 - enzyme mechanisms 91, 174
 - enzyme prediction
 - for orphan and novel reactions 244–246, 251, 257
 - enzyme properties 153, 155, 172, 180–186
 - equality constraints 107
 - ERG9* 714–715, 717
 - erythrose-4-phosphate (E4P) 14, 201, 428, 709
 - Escherichia coli* (*E. coli*) 36, 473, 556
 - bulk chemicals
 - ω -amino acids 357–359
 - diamines 360–361
 - dicarboxylic acids 361–362
 - diols 362–363
 - hydroxy acids 359–360
 - lactams 363
 - definition 341
 - fuels production
 - non-native biofuel producers 343
 - non-natural biofuels 343
 - renewable biofuels 342
 - microbial biopolymers
 - non-protein poly(amino acid)s 380–381
 - PHAs 374–379
 - polysaccharides 379–380
 - nanomaterials (NMs) 381–383
 - natural products 367–371
 - recombinant protein production 371, 372
 - membrane proteins 372, 373
 - protein-based materials 374
 - therapeutic proteins 371, 373
 - specialty chemicals
 - aromatic compounds 365–367
 - L-amino acids 364–365
 - Escherichia coli* K-12 MG1655 23, 36
 - essential genes 32, 437, 470, 473–475, 478, 488, 497, 499, 565, 626, 824
 - ethanol production 229, 233, 284, 343, 575, 611, 691–695, 697–698, 703–706
 - eukaryotic microalgae 806
 - evolutionary engineering 341, 571, 697
 - exometabolomics 260
 - exopolysaccharide 379–380
 - expression cassette 302, 310, 318, 479, 482, 737, 741, 747, 755, 760, 769
 - extended Debye–Hückel limiting law 221, 222
 - external constraints 138–139
 - external metabolites 174
 - extra-cytoplasmic function sigma factors (ECF) 493
 - extracellular alkaline cellulase Egl-237 477
 - extracellular fluxes 6, 78–79, 83–85, 91, 93, 98, 106, 111–113
 - extracellular reactions 78, 103
- f**
- FAIMS 267
 - Faraday constant 223, 227
 - β -farnesene production 713, 716

- fatty acid *de novo* biosynthesis 355, 375, 377
- fatty acid alkyl esters (FAAEs) 355
- fatty acid ethyl esters (FAEEs) 354–356
- fatty acid methyl esters (FAMEs) 354–356
- fatty acid pathway 355–356
- feedback inhibition simulation 205–207
- fermentative pathway 343, 354
- ferulic acids 588, 816, 835
- filamentous actinomycetes
genome-scale metabolic models 674–675
multi-omics studies 671–674
- filamentous fungi 313, 767, 784
A. niger 765, 776–778
A. oryzae 778–779
A. terreus 779–780
carbon catabolism 775
cell factories and products 766
CRISPR genome editing protocols for 768, 769
genetic and genome tool development 768–769
improved substrate utilization 773–775
industrially exploited 768
macromorphology of 785–788
metabolic and regulatory models 770–772
morphologies 767
natural metabolic capacities of 765
P. chrysogenum 780–781
protein production 788
secondary metabolites from 784
T. reesei 781–783
T. thermophilus 783
- fine-tuned integration of proteome constraints
coupling constraints 148, 150
pcModels 144, 145, 147
ribosome assembly reaction 148
TPI enzyme 146
- first-generation bioethanol production 691–694
- five-carbon containing prenyl isomers 822
- FK506 biosynthesis 674
- flavonoids 817, 819
biosynthesis 708, 818
in *S. cerevisiae* 709
- flavonols 418–419, 708–710, 819
- fluorescence-activating and absorption-shifting tag (FAST) protein 633
- fluorescent reporters 631–633
- 5-fluoro-dUMP 479
- 5-fluorouracil (5-FU) 479
- flux balance analysis (FBA) 6, 7, 162, 172, 215, 251
additional constraints 27, 29
analogy to deriving enzymatic rate equations 25
constrained optimization 26
dynamic mass balances 23–25
flux-concentration duality 28
genome-scale 25, 26
- flux-concentration duality 28
- flux connectivity theorem 184
- flux constraints 107
- flux control coefficient 175–180, 184, 186–191, 195–198, 201–202, 204–206, 283
- flux quotient 96
- flux summation theorem 178–179, 199
- flux vector 25
- flux-enzyme relationship 176–178
- fluxomics 50, 75, 77–79, 167, 406, 864
- FMN-based fluorescent proteins (FbFPs) 632
- FokI-cleavage domain 305
- folate production, in LAB 579
- forskolin 822–823, 834–835, 837
- forward simulation 84–85, 98, 121, 123
- Fourier-transform ion cyclotron resonance (FT-ICR) 271
- fractional labeling enrichment (FLE) 81, 82, 106, 116
- free amino acids 112, 115, 116, 735, 755

- free fatty acids (FFAs) 354, 355, 701, 735, 755
- free/independent fluxes 84
- fructose 6-phosphate 31, 140, 434, 481, 580
- fruit-specific *E8* promoter 819
- fumaric acid 783
- functional CRISPR/Cas9-sgRNA complex formation 490
- functional kinetic model 157–158, 163, 165–166
- fungal biotechnology 766, 775, 788–789
- fusafungine 785

- g**
- γ -aminobutyrate (GABA) 587
- GAP dehydrogenase (GapA) 428, 432, 748–749
- gas chromatography (GC) 114, 266
- GE-free synthetic biology 865
- GEM with enzymatic constraints using kinetics and omics data (GECKO) 139–142, 144
- gene expression knockdowns 625
- gene expression, in lactic acid bacteria 557
- gene/genetically modified organisms (GMOs) 555, 565–566, 574, 579, 590, 829, 867, 872, 873, 877
- gene-protein-reaction (GPR) 32–33, 674
- generalized mass action (GMA) 159–160
- genome annotation 7, 32, 36, 157, 168, 470, 522
- genome editing
 - definition of 301
 - of industrially relevant eukaryotes
 - CHO 317–320
 - filamentous fungi 313, 315–316
 - yeast 310–313
 - principles of 301–304
- genome editing tools
 - counter-selection and markerless genome editing 478–481
 - CRISPR/Cas in *B. subtilis* and related strains 481–486
- genome mining 581, 671, 673, 675–676, 784
 - for biosynthetic gene clusters 657–660
- genome mining tools 658, 660
 - limitations 658
- genome reduction projects in *B. subtilis* 473–477, 481
- genome-reduced strain MGB874 476–477
- genome-reduced variants, of *P. putida* 528–529
- genome-scale kinetic models 7, 156, 168
- genome-scale metabolic models (GEMs) 213, 215, 674, 770
 - internal constraints
 - membrane economics 139
 - molecular crowding 139
 - proteome constraints 139
- genome scale models (GSM) 7, 23–63, 137–151, 156, 240
- genome-scale models (GEMs) 7, 23
 - E. coli* 36–42
 - developments 50–55
 - from metabolism to the proteome 42–49
 - perspectives 56–59
- genome-wide CRISPRi 488
- genome-wide transcriptome analysis 690
- Geobacillus thermodenitrificans* 490
- geranylgeranyl diphosphate (GGDP) 758, 822–824, 828
- geranylgeranyl pyrophosphate (GGPP) 496, 713, 714, 717–718, 758
- geranylgeranyl pyrophosphate synthase (GGPPS) 496
- gibberellins 817, 826
- Gibbs free energy 214–218, 220–223, 225–228, 233, 247
 - of pseudoisomer 222
- global environmental problems, by urban and industrial activities 866

- global gene expression analyses 470
 global scale 6, 404, 803, 821, 838, 880
 global Transcriptional Machinery
 Engineering (gTME) method
 12, 366, 373, 492
glpX gene 495
 glucoamylase 776–778, 786
 glucose 6-phosphate (G6P) generation
 31–32, 165, 180, 224, 359, 413,
 422, 431, 434–435, 495, 497,
 524–525, 554, 750
 glucose-6-phosphate dehydrogenase
 495, 497, 554
 glucose-6-phosphate isomerase (PGI)
 32, 142, 162, 165, 554
 β -glucosidase 436–437, 530, 571, 697,
 774
 glucosinolates 817, 820
 L-glutamate 364, 383, 403, 405, 412,
 419–420, 427, 435–436, 587
 glutamate (GLU₁₋₅) 117
 glutamate dehydrogenase RocG 476
 glutamate racemases 497
 Glutamine Synthase (GS) 318
 glutarate production 431, 741, 742
 glutaric acid 357, 361, 362
 glyceraldehyde 3-phosphate (GAP)
 dehydrogenase approach 749
 dehydrogenase-encoding gene 496
 glycerate 809
 glycerol kinase (GlpK) 38, 495
 glycerol metabolism, in LAB 585
 glycerol transport facilitator (GlpF)
 495
 glycine betaine 829
 glycolysis 14, 31–32, 101, 112, 140,
 142, 145, 156, 161, 165, 188,
 192, 205, 224, 229, 233, 497,
 524–525, 553, 674, 704–705,
 738, 740, 743, 745, 778
 glycosylated proteins 373, 720
 glyoxylate shunt 101, 360, 472, 703,
 742, 750, 779
 Golden Rice 820
 Golgi apparatus 718–720, 821
 Golgi-derived secretory vesicles 720
 gram cell dry weight (gCDW) 8, 144,
 149
 graph-based search 243–244
 green fluorescent protein (GFP) 318,
 492–493, 631–632, 667
 guide RNA (gRNA) 308–309, 620, 663
 guilt-by-association approach 771
- ## h
- Haemophilus influenzae* 23
 “hard” constraints 138–139
 heat stress tolerance 567–569
 height equivalent of a theoretical plate
 (HETP) 264
 heme biosynthesis 721
 hemicellulosic polysaccharides 813
 hemoglobin 495, 721
 hepatitis B surface antigen (HBsAg)
 722
 hepatitis B vaccines 722
 high resolution mass spectrometry
 270, 280
 high-resolution fluxomics 406
 high-throughput metabolomics
 279–280
 Hill coefficient 184
 Hill equation 159, 206
 homogalacturonan 813
 homogentisic acid 826
 homologous recombination (HR)
 mechanism 301, 303, 406,
 559–560, 564, 616–620, 626,
 662–663, 737, 769, 807, 826,
 830, 831
 horizontal gene transfer (HGT) 861
 based, large-scale biormediation
 878
 events 868
 HR-mediated technique for genome
 editing 302, 304
 human insulin 720–721
 human papillomavirus (HPV) vaccines
 722
 Hunter’s syndrome 306
 hyaluronan 379–380
 hyaluronic acid (HA) production 435
 in *C. glutamicum* 434, 435

- hydrocortisone 717
 hydrophilic interaction liquid chromatography (HILIC) 265, 276
 hydroxy acids
 3HP 360
 4HB 360
 4-hydroxybutyric acid (4HB) 359–360
 4-hydroxycinnamic acid (p-HCA) 707–709
 3-hydroxydecanoate (3HD) 375
 3-hydroxydodecanoate (3HDD) 375, 377
 3-hydroxyhexanoate (3HHx) 375
 4-hydroxyisoleucine (4-HIL) production 403, 427
 3-hydroxyoctanoate (3HO) 375
 3-hydroxypropionate (3-HP) 375, 377, 430, 432
 3-hydroxypropionic acid (3-HP) 359–360, 585, 703, 705
 hygromycin B 315, 737, 745, 747
- i**
- i*Bsu1103 470
*i*Chip 654
 illumina sequencing 760
*i*Modulons 52–55, 57, 62
 in-depth global transcriptome 470
 inactivated whole cells 860
 INCA 117
 independent component analysis (ICA) 51
 inducible promoters 620, 627
 inequality constraints 107
 input labeling composition 104
 input labeling design 93
in silico cell 33
in silico experimental ILE design 108
 INST-¹³C-MFA 83, 123
 integrative analysis of omics data 166
 intermediates, toxicity of 247
 internal constraints 138–139
 internal metabolites 174, 179, 184, 200
 intracellular compartments 8
 intracellular enzyme kinetics 155–156
 intracellular fluxes 46, 75, 77–79, 82–84, 91, 93, 99–100, 103, 107, 112, 260
 intracellular metabolite pool size 78, 95, 106, 123
 inverse problem 85, 98, 121
in vitro enzyme assays 161
in vivo RBS-selector 667
 ion chromatography (IC) 264, 267
 ion mobility 267
 ion-pairing RPLC (IP-RPLC) 265–266, 283
 ionization techniques 268–269, 280
 irregular xylem (IRX) mutants 814
 IRX7 deficient plants 814
 isobutanol production 698–699
 isocitrate dehydrogenase Icd 496
 isoflavonoids 708, 710, 817
 isopentenyl diphosphate 354–355, 434, 757–758, 822
 isopentenyl pyrophosphate (IPP) 14, 354–355, 367–369, 661, 713–717, 757–758
 isoprenoid pathway 343, 355
 isopropanol 263, 265, 343, 354, 613
 isotope labeling experiment 100
 atom transition network specification 103–104
 input labeling composition 104–106
 metabolic network specification 101–103
 modeling and simulation 101
 isotopic labeling 78–80, 96, 98, 115
 isotopic steady state (ISS) 77, 90, 123
 approximation 115–116
 isotopic tracers 4, 6, 77, 79–80, 99
 isotopic tracing 8–9
 isotopically labelled tracer 8
 isotopologues 97, 261, 274
 isotopomer fractions 94, 96–97, 103
 isotopomers 91–98, 106, 114, 116
 itaconate 428, 430, 777, 779, 780
 A. niger 777

k

keto acid decarboxylase (KDC) 354, 697

2-keto-acid route 698

α -ketoglutarate production 741–742

ketones bioreduction 584–585

keyicin production 673

kinetic feasibility 246, 247

kinetic model

applications 166–167

approximative rate expression 159–160

description 156

functional 157–158

mechanistic rate expressions 158–159

perspectives 167–168

rate expressions 160–166

scope 156–157

toy example 164–165

toy model 164–165

yeast 165–166

kinetome 51, 168

kirromycin biosynthesis 656, 657

knowledge bases 24, 35, 57, 62, 404, 838, 862

kojic acid

A. oryzae 778, 779

k-OptForce 41

l

L- and/or D-glutamic acid monomers 495

L-arabinose 283, 695, 697

labeled substrate 77, 80–81, 99, 104, 108, 110–113, 116

labeling enrichments 81–83, 85, 90–91, 100, 103, 106, 109, 113, 115–117, 121, 123

lactams 357, 363

lactate dehydrogenase (LDH) 196, 362, 377, 423–424, 434–435, 554, 571–573, 577, 587–588

lactic acid 195, 572, 573, 613, 705

lactic acid bacteria (LAB) 555

as biocatalysts 583–589

bacteriocins 581–583

biotransformations 587–588

bulk chemical production

acetoin 575–577

butanediol-isomers 577–578

ethanol 575

butanol production 588

CRISPR-Cas-technology for genome editing 563–565

features and phylogeny of 552, 553

fermentation 552

food ingredients

acetaldehyde 574–575

alanine 574

diacetyl 574

lactic acid 572, 573

gene expression 557–559

genetic engineering of 559–565

glycerol conversion 585–587

heat tolerance

acid tolerance 569

oxygen tolerance 570–571

host for plant metabolite production 588

ketones bioreduction 584–585

metabolism of 553–555

multistress-resistance 567

plasmid integration by homologous recombination 559–560

plasmid integration using phage attachment sites 560–561

polyols production 579–580

preservative effect 551

recombineering based genetic engineering 561–563

roles and functions 551

shuttle vectors 556–557

starter cultures for food fermentation 565–567

stress tolerance

heat tolerance 567–569

substrate utilization routes 571–572

therapeutic proteins production 580–581

thermotolerance 568

transformation of 556–557

vitamins production

cobalamin (vitamin B12) 579

- lactic acid bacteria (LAB) (*contd.*)
 folate (vitamin B9) 579
 riboflavin (vitamin B2) 578
- lactic acid production 569, 572, 587, 705
- Lactobacillus casei* 556, 561, 563–564, 568–569, 577, 580, 582, 584, 587
- Lactobacillus reuteri* 561–562, 579, 584, 586
- Lactococcus lactis* 473, 556–558, 560, 570
 for bulk chemicals production 576
 as drug delivery vehicle (DDV) 580
 for over-producing flavor compounds 573
- lanthipeptides 581–582
- ligD* positive strains 487
- lignans 817
- lignocellulose 530, 694, 782
- lignocellulosic biofuel production 694
- limiting rate 172, 181, 183
- lin-log modeling approach 160
- linear ion traps (LITs) 270
- linear plus linear homologous recombination (LLHR) 662
- linearized statistics 89–90
- lipid synthesis 747, 833
- lipid-rich yeast 753
- lipolase 313
- lipopeptide surfactin 497
- Lisianthus nigrescens* 834–835
- liquid chromatography (LC) 114, 264–266, 669
- liquid–liquid extraction (LLE) 263
- lithium acetate method 737
- lovastatin 653, 779–780
- low resolution mass spectrometry 269–270
- Lpd1 740
- lycopene, in *S. avermitilis* 667
- L-lysine 110, 357, 359, 361, 364, 403–405, 413, 415–416, 419–423, 425–426
- lysophosphatidate acyltransferase (LPAAT) 204–205
- m**
- machine learning approaches 241, 242, 249, 660
- maize 806, 821
- malate synthase 472, 697, 810
- malate–pyruvate–oxaloacetate cycle approach 749
- malic acid production 703–704
 A. oryzae 779
- maltose consumption 477
- mandelic acid 366, 378–379
- Manihot esculenta* 832
- mannitol 420–421, 579–580
 utilization 415–416
- mannose 414
 mannose phosphoenolpyruvate-dependent phosphotransferase system 481
 mannose-specific transporter ManP 481
- manPA* alleles 481
- manual pathway design 238
- Mariner-transposable *Himar1*-based systems 617
- markerless-deletion system 619
- Markov chain Monte Carlo (MCMC) approach 89
 sampling 26
- mass isotopomers 97–98, 114, 116–117
- mass spectrometry (MS) 268
 acquisition modes
 for targeted metabolomics 271–272
 for targeted MS 272
 for untargeted metabolomics 272
 features 268
 high resolution 270–271
 ionization techniques 268–269
 low resolution 269–270
- Mathieu equations 270
- matrix effect 263, 268–269, 279
- matrix-assisted laser desorption ionization (MALDI) 269–270, 280
- max-min driving force (MDF) of pathway 282

- Maximum Likelihood Estimator (MLE) 163
- maximum reaction velocity 25
- mCherry-reporter cassette 319
- ME models 42–49, 57
- mechanistic rate expressions 158–160
- medium chain length PHA (MCL-PHA) 375, 378
- meganucleases 302–304, 320
- membrane bound cytochrome P450 (P450) enzymes 812
- metabolic control analysis (MCA) 6, 153, 171, 173, 283
- aromatic amino acids, bacterial production of 200–202
 - based methods 166
 - concentration control coefficient 179–180
 - demand for product 194–195
 - flux control coefficient 175–176
 - flux summation theorem 178–179
 - flux–enzyme relationship 176–178
 - inhibition of competing pathways 195–196
 - limitation of 171, 188
 - linking control coefficients to enzyme properties 181
 - alterations of enzyme activity 188–190
 - block elasticities 186
 - control coefficients and elasticities 184–186
 - elasticity coefficient 181–184
 - enzyme rate equations 181–184
 - feedback inhibition 186–188
 - feedback inhibition, abolishing 191–194
 - top–down analysis 186
 - metabolic steady state 174–175
 - Universal Method 199–200
 - yeast tryptophan synthesis 197–198
 - yield impacts 203–205
- metabolic engineering
- bioenergetics in life 213–214
 - of *Bacillus*
 - activity-independent screening of target molecule synthesis 492–493
 - biotechnological application 493–497
 - generally regarded as safe 470
 - minimal cell concept 472–478
 - optimization, standardization, and modularity in gene expression 490–492
 - physiological traits and circuits 470–472
 - quality presumption of safety 470
 - tools for genome editing 478–490
 - cellular metabolism and physiology
 - ‘omics’ technologies 7–9
 - FBA 6, 7
 - isotopic tracing 8, 9
 - MCA 6
 - MFA 6, 7
 - combinatorial metabolic engineering 12–14
 - Escherichia coli* 341–384
 - goal of 171
 - history and overview of 3
 - host organism selection 15
 - industrial biotechnology 17
 - rational metabolic engineering 10–11
 - strain development process 17, 18
 - substrates 15–16
 - synthetic biology 16
 - systems metabolic engineering 14
- Metabolic Engineering: Principles and Methodologies 3
- metabolic flux analysis (MFA) 6, 7
- ¹³C-MFA 97–99, 124–125
 - ¹³C-MFA variants 76–77
 - bidirectional reaction steps 95–96
 - biotechnologically relevant organisms 108
 - carbon atom transitions 91–93
 - extracellular fluxes 111–112
 - flux constraints 107
 - fluxomics 77–79
 - from the data to the intracellular fluxes 82–83

- metabolic flux analysis (MFA) (*contd.*)
 - in silico* experimental ILE design 108
 - input labeling design 93–94
 - INST-¹³C-MFA 83–84, 123–124
 - introduction 73–77
 - isotope labeling experiment 100–108
 - isotopic labeling 79–81
 - isotopic steady state approximation 115–116
 - isotopomer fractions 96–97
 - isotopomers 94–95
 - labeled substrate 112–113
 - measurement specification 106–107
 - metabolic and isotopic stationarity 110–111
 - metabolic and isotopic stationary state 90–91
 - metabolomics 113–115
 - natural isotope abundance 116–117
 - parameter fitting 84–86
 - simulation of labeling data and flux estimation 117–123
 - statistical analysis 86, 89–90
 - statistical evaluation and optimal experimental design 99–100
- metabolic pathway design 237–238
- metabolic pseudo-steady state approaches 76, 109
- metabolic steady state (MSS) 77, 173–175, 182, 188, 281
 - assumption 77
- metabolism 153
 - of LAB 553–555
 - metabolism 523
 - sugar 554
- metabolite extraction 8, 262
- metabolomics 8, 113, 259
 - analytical techniques
 - sample preparation 262–264
 - separation techniques 264–267
 - applications 281–285
 - calibration curves 261
 - challenges 259
 - data analysis 272–277
 - and interpretation 277–279
 - engineer medium composition 285
 - experimental design 260
 - improving stress tolerance 284–285
 - internal standards 261
 - pathway design by thermodynamic analysis 281–283
 - reduction of side products and metabolite damage 284
 - sequences and standards 261–262
 - targeted and untargeted 260–261
- metabolons 825, 831–833
- MetaCyc 101
- metallo-proteome 43–45, 55
- meta-organismal catalysts 875
- methotrexate (MTX) inhibits 317
- methyl anthranilate 366, 404
- 2-methyl-D-erythritol 4-phosphate (MEP) pathway 822
- methylerythritol-4-phosphate (MEP) 355
- mevalonate (MVA) pathway 354, 355, 822
 - in *S. cerevisiae* 714
- mevalonate diphosphate (MVAPP) 758
- mevalonate pathway 588–589, 757–759
- Michaelis constant 159, 181
- Michaelis–Menten constant 25
- Michaelis–Menten formula 153–154
 - enzyme kinetics 154
 - formulation 159
- Michaelis–Menten kinetics 7, 154, 164
- Michaelis–Menten reaction mechanism 25
- microalgae 803, 806, 811, 829–831
- microbial activities, multi-scale propagation of 869
- microbial biocatalysts 4
- microbial biopolymers
 - non-protein poly(amino acid)s 380
 - PHAs 374–379
 - polysaccharides 379–380
- microbial consortia 874, 879
- microbiological agents for bioremediation 860

- microfluidics 13, 280–281, 483, 654, 784
 microhomology-mediated end-joining (MMEJ) 301, 302, 319
 minGenome 41
MiniBacillus 494
MiniBacillus framework 475
 minimal cell concept
 genome reduction projects in *B. subtilis* 473–476
 minimal genomes 472–473
 productivity of genome-reduced strains 477–478
 minimal genomes 61, 472–473, 499, 789
 missing values 85, 274
 mixed-integer linear program (MILP) 38, 215, 227–228
 mixed-integer nonlinear program (MINLP) 41
 monoclonal antibodies (mAbs) 371, 373
 monoterpene indole alkaloids (MIAs) 370, 710–712
 monoterpenes, in *S. cerevisiae* 716
 Monte Carlo based approach 163
 MPD pipeline 787–788
M. thermoacetica gas fermentation 751
 multi-strain reconstructions 33
 multiple reaction monitoring (MRM)
 method 271
 multiplex automated genome editing/engineering (MAGE) 342, 526, 863
 multiplex genome editing 486–487
 multivariate statistics 278
 Mummichog algorithm 279
 mutagenic ssDNA recombineering 870
mutS mutations 569
Mycoplasma mycoides JCVI-syn3.0 strain 473
 mycosporine-like amino acid (MAA) 423
- n**
 NADH oxidase (NOX) of *Lactococcus lactis* 196
 NADPH-P450 oxidoreductase *SbPQR2b* 825
 NADPH-P450 oxidoreductases (PORs) 817
Nannochloropsis oceanica 806, 830
 nanomaterials (NMs) 381–383
 nanopore sequencing technology 655
 nanopore sequencing, in *Y. lipolytica* genome 760
 nanostructure-initiator mass spectrometry (NIMS) 280
 natural abundance (NA) 80
 correction 116–117
 NATural Deep Eutectic Solvent (NADES) 834–835, 837
 natural isotope abundance 116–117
 natural isotope enrichments 105
 natural products
 alkaloids 368, 370
 phenylpropanoids 368–370
 polyketides 368, 370–371
 terpenoids 367–369
 naturally labeled ¹²C glucose 80
 N-containing bioactive natural products 820–821
 network data representation 242
 network reconstruction
 availability of GEMs 35
 basic principles 30–32
 computational queries 32–33
 curation 32
 genomic basis 32
 knowledge bases 35
 scope expansion 33–35
Nicotiana benthamiana 807
 nicotinamide adenine dinucleotide phosphate (NADPH) 714, 808, 809
 Nisin controlled gene expression (NICE) system, in LAB 557, 558, 565
 nisin Z 582
nisK 557, 558
nisR 557, 558

- non-homologous end joining (NHEJ)
 - mechanism 301, 302, 313, 314, 318, 489, 619, 626, 663, 737, 741, 745, 747, 760
 - non-native biofuel producers
 - fatty acids pathway 355–356
 - fermentative pathway 343–354
 - isoprenoid pathway 355
 - keto acid pathway 354–355
 - non-natural biofuels 343
 - non-oxidative pentose phosphate
 - pathway (PPP) 96, 101, 284, 285, 495, 553, 554, 748, 750, 751, 753, 754
 - non-protein poly(amino acid)s 380–381
 - nonribosomal peptide synthetases (NRPSs) 371, 496, 534, 657, 667
 - R,S*-norlaudanoline 370
 - normal-phase liquid chromatography (NPLC) 265
 - novel reactions 244–245, 251, 257, 583
 - nuclear localization signal (NLS) 306, 308
- O**
- Obiwarped method 274
 - off-target effects 305, 307, 309, 316, 319
 - oleochemicals 699
 - oligo-annealed promoter shuffling (OAPS) 491
 - oligosaccharides 412, 414–415, 773
 - omega-3 fatty acid 818
 - 4'-*O*-methyltransferase (4'OMT) 368, 370
 - omics' technologies 7–9
 - OPENFLUX 117
 - OptForce 38, 41
 - optimal experimental design (OED) 89, 99–100, 101, 108, 109, 123
 - OptKnock 38
 - OptStrain 38
 - orbital trap 270
 - Orbitrap instruments 270, 271
 - organic acids production
 - S. cerevisiae* 702
 - orotate transporter (*oroP*) 559, 560
 - Oryza sativa* 806
 - oxidative pentose phosphate pathway 553, 748
 - oxidative TCA cycle 703, 704
 - OxidizeME 43, 46, 48
 - 2-oxoglutarate 419, 476, 711
 - oxygen tolerance 570–571
- P**
- paclitaxel 367, 717, 818
 - pangenome 41, 61, 522
 - paralogous proteins 473
 - parameter covariance matrix 89
 - parameter fitting 84–86, 96, 98, 107, 116, 121, 123, 163
 - parametric Monte Carlo bootstrap 89
 - pathway design 238
 - available tools for 247–249
 - practical example of 249
 - successful applications of 249
 - pathway feasibility 246–247
 - pathway search 237, 242–243, 244, 249
 - algorithm 244
 - PCR-generated sgRNA expression 487
 - P450-dependent biosynthetic pathway 824, 825
 - peak grouping 274
 - peak picking 273–274
 - pectin matrix 813
 - penicillin 202–203, 420, 653, 769, 780, 781
 - penicillin-producing fungi 313
 - Penicillium chrysogenum* 767, 780
 - enzyme set for plant polysaccharide degradation 773
 - GEMs for 770
 - secondary metabolite production 774
 - X-ray microcomputed tomography (μ CT) 787–788
 - pentose fermentation rate 695
 - pentose phosphate pathway (PPP) 96, 101, 156, 229, 284, 285, 495,

- 524, 553, 554, 674, 695, 748, 750, 753, 754
- pentose sugars 413, 553, 695, 697
- γ -PGA biosynthesis 495
- pG⁺ host system 560
- phage-assisted continuous evolution (PACE) 13
- phenylalanine ammonia lyase (PAL) 359, 367, 707, 708, 819, 820
- 3-phenyllactic acid (PLA) 375, 378, 587, 588
- phenylpropanoid biosynthesis 819
- phenylpropanoid pathway 707, 819, 833
- phenylpropanoids 367, 368–370, 706–710, 813, 817, 819
- phosphite oxidoreductase (PtxD) 829
- phosphoenolpyruvate carboxykinase gene 416, 422, 431, 496, 744
- phosphofructokinase (PFK1) 31, 180, 188, 191, 414, 432, 497, 498, 554, 674, 692, 776
- 6-phosphofructokinase 497, 498, 674
- butanol production 698
- phosphoglucose isomerase (PGI) 31, 32, 33, 142, 165, 692
- 3-phosphoglycerate 165, 692, 809
- phosphoglycerate mutase (PGM) 165, 692
- phosphotransferase systems (PTS) 201, 414, 415, 428, 522, 523, 554, 555, 580
- photorespiration 809, 810
- photosynthetic cells
- biosustainable industrial production platforms 806–808
 - plants 803–805
 - solar radiation 805–806
- photosynthetic organisms
- cyanobacteria 808
 - metabolic engineering strategies 810
 - photorespiration 809
 - ribulose-1,5-bisphosphate 809
 - Rubisco 808
 - thylakoids 808
- phyloquinone 826
- physiological effects 8, 499
- L-pipecolic acid 403, 426
- plant bioactive natural products
- phenylpropanoids 817
 - synthesis and regulation of 817–818
 - terpenoids 817
 - upregulated anthocyanin synthesis 818–819
- plant cell wall 530, 803, 814, 816, 813
- plant metabolic engineering 803, 804, 820, 838
- plant metabolites 588–589, 807, 822
- plant-derived taxadiene synthase 495
- plants 803–808
- plasmid copy number effect 477
- plasmid-based CRISPR/Cas9 systems 482
- plastoquinols 826
- plastoquinone 809, 826, 829
- pollutant-responding whole cell biosensors 865
- poly(diaminobutyric acid) 380
- poly(diaminopropionic acid) 380
- poly(glutamic acid) 380, 381
- poly(lactate-*co*-glycolate) (PLGA) 377, 378, 379
- poly(lysine) 380
- poly(PhLA-*co*-3HB) production 379
- poly- γ -glutamic acid (γ -PGA) 494, 495
- polyglutamate (PGA) 435–436, 494, 495
- polyglutamate synthesis 495
- polyhydroxyalkanoates (PHAs)
- energy and redox storage material 374
 - MCL-PHA 375, 378
 - PHA (SCL-PHA) 375
 - PhaCs 378
 - PLGA 379
 - poly(3HB) 375, 377
 - poly(PhLA-*co*-3HB) production 379
- polyketides 14, 367, 368, 370–371, 534, 581, 713, 754, 775
- polymerase chain reaction (PCR) 12, 311, 478, 481, 482, 487, 527, 558, 662, 663, 736

- polysaccharides 374, 379–380, 408, 530, 773, 775, 782, 813, 814, 815, 816
 pOri plasmid 560
 practical non-identifiability 100
 pravastatin 781
 precursor compound 237, 242, 243, 253
 P43 reference promoter 491
 prenyl transferases 822
 principal component analysis 55, 278
 pristinamycin 663, 664
 pro-vitamin A 820
 productivity of genome-reduced strains 477–478
 profile likelihoods 89
 proinsulin 720, 721
 promoters 627–630
 promoters, in actinomycetes 667
 1,2-propanediol 428, 432, 706
 1,3-propanediol (1,3-PDO) 360, 362, 363, 375, 377, 428, 430, 432, 519, 585, 586
 protein precipitation 262, 263
 protein sequence 47, 244, 246
 protein structures 35, 47, 50, 55, 57, 632, 782
 protein-based biopharmaceuticals 371
 proteinogenic amino acids 112, 114, 115, 116, 403, 406, 419, 655, 657
 proteome constraints
 coarse-grained integration of 139–144
 fine-tuned integration of 144–150
 proteome-constrained models (pcModel) 144, 145, 147, 150, 168
 protospacer adjacent motif (PAM) sequence 308, 309, 407, 620
Prunus dulcis 818
Pseudomonas putida 473, 528
 EDEMP cycle 524
 in silico analysis 522
 in silico metabolic potential 522
 aromatic molecules, production of 532–534
 biosynthesis of natural products 534
 carbon substrate range, expansion of 529–530
 characteristics of 521–522
 CRISPR/Cas-based gene editing techniques 526
 features 529
 genome-reduced variants 528–529
 glucose uptake 523
 glycerol metabolism 523
 high-efficiency multiple genomic site engineering (HEMSE) of 526
 nutritional landscape 530
 organic acids, production of 533
 oxygen-dependent lifestyle engineering 530–532
 solvent-tolerant strains 521
 substrate utilization and core metabolism 522–524
 synthetic biology tools for 524–528
 taxonomic credentials 521
 xylose catabolism, pathways for 523
Pseudomonas putida KT2440 357, 519
ptb 619, 627
 putative BCAA permease 496
 putrescine 359, 360, 361, 412, 423
 pyrazines 433
 pyruvate 741
 -acetaldehyde-acetate-AcCoA route 756
 and α -ketoglutarate production 740
 pyruvate decarboxylase negative strain (PDC) 704, 705
- q**
 quadrupoles 269–271
 quantum mechanical/molecular dynamics (QM/MD) 216
 quasi-steady state assumption (QSSA) 25, 174
 quenching 110, 114, 262, 281, 811, 830
 quorum sensing systems 876
- r**
 random mutagenesis 12, 304, 378, 419, 491, 532, 566, 567, 615–617, 670, 781

- rate expressions 153, 156–166, 163, 164, 167, 168
- rate-limiting steps 173, 365, 721
- rational metabolic engineering 9, 10–11, 613
- reaction directionality 214, 242
- reaction prediction 237, 240–241, 242
- reaction reversibility 214
- Recombinant DNA Biotechnology III + The Integration of Biological and Engineering Science 3
- recombinant DNA technologies 3, 862
- recombinant proteins 371, 372, 404, 436, 718–723, 828, 830
- recombinant protein production
 membrane proteins 371, 372, 373
 protein-based materials 374
 therapeutic proteins 371–373
- recombinant RNA 437
- Recombinase-Mediated Cassette Exchange (RMCE) 319, 320
- recombineering based genetic engineering, in LAB 561–562
- reduced-genome variants, of *P. taiwanensis* VLB120 529
- RelA/SpoT homologues 471
- renewable biofuels 342
- Repeat Variable Diresidues (RVDs) 306, 307
- reporter-guided mutant selection (RGMS) 670
- repression under secretion stress (RESS) 778, 782
- rep60*-specific sgRNA 487
- resveratrol 369, 418, 818
- retention time 264, 266, 272, 274, 276
- (*S*)-reticuline derived morphine type alkaloids 824
- retrobiosynthesis 241–242, 243, 251
- retrobiosynthetic approach 115, 243
- reverse catabolite repression strategy 523
- reverse-phase liquid chromatography (RPLC) 265, 266, 268, 276, 283
- reversible Michaelis–Menten equation 181, 182
- rhamnogalacturonan 813
- Ribo-seq 61
- ribosomal binding sites (RBSs) 433, 667, 668, 871
- ribosomal proteins 147, 473, 476
- riboswitches 493, 634, 670, 865
- ribozymes 316, 312
- ribulose-1,5-bisphosphate 808, 809
 carboxylase-oxygenase (Rubisco) 808
- rice 571, 778, 806, 809, 816, 818, 820
- RNA sequencing 48, 51, 53, 61, 405
- roseoflavin 578
- RPLC 265, 266, 268, 276, 283
- rRNAs 473
- 16s rRNA-based unrooted phylogenetic tree, of LAB 552–553
- S**
- SABIO-RK13 161–162
- Saccharomyces cerevisiae*
 alkaloid compounds production 710
 aromatic amino acids 708
 commodity chemicals production
 diols 706
 organic acids 702–705
 cytosolic fatty acid synthesis 699
 fatty acid synthesis 699–700
 fatty acids synthesis 699–700
 first-generation bioethanol production 691–694
 flavonoids biosynthesis 710
 higher alcohol production 695–697
 history 689
 insulin analogue expression 721
 mevalonate and sterol pathway 713–714
 monoterpenes, triterpenes, and isoprenoids production 716–718
 phenylpropanoids production 706–710
 protein secretory pathway 718–719
 recombinant proteins production 718–723

- Saccharomyces cerevisiae* (*contd.*)
- second generation bioethanol
 - 694–697
 - timeline 690
 - virus like particles in 721–723
 - S-adenosylmethionine (SAM) synthesis 356, 366, 493
 - Salinispora* genomes 672
 - SAM-dependent methyltransferase (AAMT1) 366
 - sample batches 275
 - sample-specific variations, correction of 275
 - S. cerevisiae* GEM 140, 157
 - scrambling reactions 102, 104, 107
 - second generation bioethanol 694–697
 - second law of thermodynamics 213–215, 227
 - Secondary Metabolite Bioinformatics Portal 658
 - secondary metabolites 653, 655, 665, 673
 - biosynthesis 660–671
 - BGC cloning for heterologous expression 661–663
 - genome mining, software for 658, 659
 - host strain selection, for heterologous expression 660–661
 - genome mining, software for 658
 - related bioinformatics tools 658
 - sedoheptulose-1,7-bisphosphatase 830
 - selected reaction monitoring (SRM) 271
 - sequencing-based approaches 655
 - sesquiterpenoid artemisinic acid 829
 - sgRNA-guided Cas9 488
 - shallow' alleleome 34
 - shikimate *p*-coumaroyl transferase 816
 - shinorine production, in *C. glutamicum* 423, 424
 - short chain length PHA (SCL-PHA) 375
 - short-chain alcohols 432, 534, 697
 - SigB-controlled general stress response 471
 - SigB-controlled regulon 471
 - sigma factor SigB 471
 - signal-recognition particle (SRP) 718
 - simultaneous saccharification and fermentation (SSF) 694
 - single cell metabolomics 280–281
 - single-gene knockout (SKO) 33, 34
 - single-strain multi-step process *vs.* consortium-based distributed catalysis 874–875
 - site-directed mutagenesis 357, 582, 711
 - SNPeffect 41
 - Solanum lycopersicum* 819
 - solar radiation 805–806, 825
 - solid-phase extraction (SPE) 263, 264
 - Sophora japonica* 834
 - sorbitol 579, 580, 694
 - space charging 270
 - SpCas9-mediated dsDNA cleavage 490
 - specialized metabolites 653, 804, 805
 - spectinabilin gene cluster 671
 - SporeWeb 470
 - Spy*Cas9 624, 625
 - squalene 714, 715, 717
 - S-reticuline by an epimerase (STORR) 368, 370
 - Standard European Vector Architecture (SEVA) 525, 527
 - statistical analysis 86–90, 122, 161, 163–166
 - sterol pathway, in *S. cerevisiae* 714
 - stilbenes 418, 817
 - stoichiometric coefficient 25, 27, 31, 138, 139, 140, 143, 215, 754
 - stoichiometric feasibility 246
 - stoichiometric matrix-based search 243
 - stoichiometric pathway evaluation 249, 251
 - strain development methods 566
 - strain development process 17, 342
 - strand invasion 302

- Streptococcus thermophilus* 308, 555, 565
- Streptomyces*
- antibiotics producers 673
 - biosensor 669
 - metabolic engineering 654
 - species 489, 661
 - strains 473
- Streptomyces coelicolor* 659, 660, 663, 666, 670, 673, 675
- genome-scale metabolic models 674–675
- Streptomyces tsukubaensis* 673
- genome-scale metabolic models 674–675
- streptomycin 527, 665
- streptothricin 665
- stressME model 43, 46
- structural non-identifiability 100
- structural systems biology 35, 55, 56
- S-styrene oxide 366, 367
- suberin 813
- substrate mixture 94, 104, 105
- substrate utilization routes, LAB 571
- subtilisin-like alkaline protease M 477
- SubtiWiki 470
- succinate dehydrogenase (Sdh) complex 360, 704, 743, 744
- succinate production 343, 412, 743, 744
- succinic acid 361, 362, 690, 703, 704, 743
- succinylase 92, 359
- sugar metabolism, of lactic acid bacteria 554
- supercritical fluid chromatography (SFC) 264, 266, 267, 268
- supervised methods, in untargeted metabolomics 278
- surfactin 494, 497
- surfactin biosynthesis 497
- switchgrass 816
- synthetic biology 862
- metabolic engineering 16
- synthetic biology agents (SBAs) 872, 873, 874, 877
- synthetic biology-based technologies for large-scale bioremediation 868–869
- synthetic morphologies 875
- synthetic promotor libraries (SPL) 557–558
- synthetically lethal gene pairs 32
- systems biology 11, 14, 28, 35, 36, 41, 55, 56, 63, 73, 181, 341, 404, 438, 519, 520, 614, 627, 654, 672
- systems metabolic engineering 5, 9, 14, 73, 341, 342, 383, 384, 404–407, 420, 424, 429, 435, 671–675, 776
- t**
- target compound 237, 238, 240, 241, 242, 243, 246, 249, 250, 251, 660, 663, 674, 817, 818, 831, 861, 864, 865
- targeted metabolomics 260–261, 262, 268, 272, 273, 274, 275, 276, 277, 278, 284, 285
- target gene *egl-237* 477
- TATA-box 312
- taxa-4,11-diene 496
- taxadiene 368, 369, 495, 496, 717, 830
- Taylor cone 268
- TCA cycle 229
- in cancer cells 4
- temperature-sensitive derivative pE194ts 481
- temperature-sensitive pSG5 *ori* 481
- temporal control 11
- temporal drifts 275
- terminators 436, 612, 633, 634, 667
- terminators, in actinomycetes 667
- terpenes 367, 712–714, 775, 812
- terpenoid production 713, 718, 812
- terpenoids 367–369, 433, 534, 712, 713, 714, 716, 717, 718, 817, 821, 822, 824, 825, 830, 837
- Terraforming Earth' approach 868
- terrestrial charophycean green algae 805

- tert*-butyl dimethylsilyl (TBDMS) 117, 118
- tetLM* riboswitch 486
- tetracycline 486, 581, 627, 653, 673
- tetrahydro-cannabinoid acid synthase 837
- L-theanine production 427
- theophylline responsive riboswitch 634, 670
- therapeutic proteins 371–373, 552, 580–583
- thermodynamic feasibility 214, 232, 237, 246–247, 251, 253, 282
- thermodynamic flux analysis (TFA) 215, 227, 228, 229, 232, 247, 251, 252, 253
- thermodynamic pathway evaluation 249, 251–257
- thermodynamics-based flux analysis (TFA) workflow 215
 - characterizing feasible concentration space 229–233
 - compartment-specific ionic strength and pH 220–221
 - constraining flux space with metabolomics data 228–229, 232
 - estimation of standard free energies of formation 216–221
 - free energy of formation for isomer distributions 221–223
 - mathematical formulation 227–228
 - model curation 215–216
 - transformed free energies of reaction 223–227
- thermostable cellulases 782
- thermostable ThermoCas9 490
- Thermothelomyces thermophilus* 766–767, 774, 783
- L-threonine 359, 364, 365, 431
- thylakoids 808, 821, 831, 837
- thymidylate synthase 479, 581
- time-course simulations of dynamic processes 166
- time-of-flight (TOF) MS 114, 270, 271, 272, 273, 274, 405
- time-resolved metabolomic measurements 281
- tocochromanols 826, 828
- tocopherols 818, 826, 828
- tocotrienols 826, 828
- top-down control analysis 186, 204
- toxic pyrimidine analogue 5-fluorouracil (5-FU) 479, 618
- toxin-antitoxin systems 479, 619
- toy model 142, 145, 148, 164
- TP901-1 integration system has 561
- trans-activating RNA (tracrRNA) 308, 309, 482
- transcription factor (TF)-based biosensors 493
- Transcription-Activator Like Effectors (TALEs) 306
- Transcription-Activator Like Effector Nucleases (TALENs) 304, 306–308, 310, 315, 318
- transcriptional regulatory networks (TRNs) 51
- transcriptomics 8, 259, 405, 413, 470, 589, 672, 673, 675, 690, 769, 771, 778, 837
- transformation-associated recombination (TAR) 662
- trans*-4-hydroxyproline (4-HYP) production 403, 426–427
- triacetic acid lactone (TAL) production 756–757
- triacylglycerols (TAGs) 673, 735, 736, 745, 747, 748, 751, 753, 754, 755, 756
- triacylglycerols production
 - Y. lipolytica*
 - cytosolic acetyl-CoA availability 753–754
 - desaturation of fatty acyl chains 747–748
 - lower raw substrate cost 749–753
 - pathway yield through balancing redox cofactors 748–749
 - push-and-pull strategy 747
 - Triticum aestivum* 806
- tricarboxylic acid (TCA) cycle 156, 472, 522, 703

- tricarboxylic citric acid cycle (TCA) 4,
101, 110, 124, 156, 229, 233,
362, 407, 413, 419, 421, 426,
427, 472, 403, 406, 674, 703,
704, 705, 739, 742, 743, 750,
751
- Trichoderma reesei* 767, 771, 781
enzyme set for plant polysaccharide
degradation 773
growth on cellulose 774
overexpression of hybrid
transcription factor in 774
- 2,4,5-trimethyl-1,3-dioxolane (TMDX)
284
- triple-quadrupole (QQQ) instruments
271
- Triticum aestivum* 806
- tRNAs 147, 473, 712
- type I-B CRISPR systems 624
- type II CRISPR system 620, 624
- tyrosinase (TYR) 370, 382, 383, 778
- L-tyrosine 365, 366, 369, 370, 379, 419,
707–710
- tyrosine-derived cyanogenic glucoside
dhurrin (D-glucopyranosyl-
oxy-(S)-p-hydroxymandelo-
nitrile) 824–825
- U**
- ubiquinone 829
- UDP-Glucose 380, 435, 498, 588, 824,
825
- UDP-glucosyltransferase mediated
de-toxification 824
- UDP-N-acetyl-glucosamine 497
- UDPG-glucosyltransferase *SbUGT85B1*
825
- unfolded protein response (UPR) 719
- univariate intervals 89
- Universal Method 199, 200, 564
- unlabeled isotopomer 94
- unsteady FBA (uFBA) 27
- untargeted metabolomics 260–261,
268, 272–278, 284, 285
- untargeted MS data processing
annotation 276–277
missing values 274
- normalization approach 275
- peak alignment and retention time
correction 274
- peak grouping 274
- peak picking 273–274
- preprocessing step 273
- upper glycolysis in *S. cerevisiae*
139–140, 142
- upregulated anthocyanin synthesis
818–819
- uracil-phosphoribosyltransferase
(UPRTase) gene *upp* 479, 560
- uridine diphosphate-glucuronic acid
497, 498
- V**
- valerolactam 357, 363, 534
- L-valine 364, 365, 405, 419, 431
- vanilla orchid 824, 834, 835
- Vanilla planifolia* 824, 834
- vanillin 417, 588, 835, 837
- vegetative SigA-type promoter 477
- very-long-chain fatty acid
(VLCFA)-derived chemicals
702
- violacein 404, 423, 433
- Viridiplantae 806
- virus like particles (VLPs), in *S.*
cerevisiae 721
- vitamin E 818, 825, 826, 828
- W**
- waste-free circular economy 867
- weighted sum of squared residual (SSR)
86, 89, 121, 527
- wheat 571, 806, 809
- whole-cell biocatalysis 519, 520, 524,
589
- X**
- XlnR transcriptional regulator 778
- xylan production 814–816
- xylo-oligosaccharides (XOSs) 412,
414, 415
- xylose 408
inducible *PxyIA* 486
inducible promoter *PxyIA* 488, 627

y

Yarrowia lipolytica 15, 285

applications 736

β -carotene production 757–759

cytosolic acetyl-CoA 753–754

eicosapentaenoic acid production
755–756

genetic engineering tools for
737–738

genotypic features 735

homologous recombination
mechanism 737

lactose as carbon source 752

NHEJ mechanism 737

opportunities and challenges
759–760

phenotypic features 735

proteases secretion 735

short-chain organic acid production
738

citrate 738–740

pyruvate and α -ketoglutarate
740–741

succinate 743–745

triacetic acid lactone (TAL)

production 756–757

triacylglycerol production 746,
747–748, 750

de novo biosynthesis 745–746

cytosolic acetyl-CoA availability
753–754

desaturation of fatty acyl chains
747–748

lower raw substrate cost 749–753

pathway yield through balancing
redox cofactors 748–749

push-and-pull strategy 747

yeast 310–313

S. cerevisiae 689

Y. lipolytica 735

yeast tryptophan synthesis 197–198

y-genes 36

yellow fluorescent protein (YFP) 632

z

Zea mays 806

zinc-finger nucleases (ZFNs) 304–306,
307, 308, 310, 318, 320

